TY - JOUR
T1 - A model for predicting size distributions delivered from pMDIs with suspended drug
AU - Stein, Stephen W.
AU - Sheth, Poonam
AU - Myrdal, Paul B.
PY - 2012/1/17
Y1 - 2012/1/17
N2 - A new model has been developed for predicting size distributions delivered from pressurized metered dose inhalers (pMDIs) that contain suspended drug particles. This model enables the residual particle size distribution to be predicted for a broad range of formulations. It expands on previous models by allowing for polydisperse micronized input drug, multiple suspended drugs, dissolved drug, and dissolved or suspended excipient to be included in the formulation. The model indicates that for most pMDI configurations, the majority of droplets contain no drug or a single drug particle and the residual particle size distribution delivered from the pMDI is essentially equivalent to the size distribution of the micronized drug used in the formulation. However, for pMDIs with a high drug concentration or that use small micronized drug particles, there can be a substantial fraction of the droplets that contain multiple drug particles. The residual particle size distribution obtained from these pMDIs can be substantially larger than the size distribution of the micronized drug. Excellent agreement was observed between size distributions predicted using this model and those obtained from experimental cascade impactor measurements (r 2 = 0.97), thus demonstrating the ability of the model to accurately predict the size distributions obtained from suspension pMDIs.
AB - A new model has been developed for predicting size distributions delivered from pressurized metered dose inhalers (pMDIs) that contain suspended drug particles. This model enables the residual particle size distribution to be predicted for a broad range of formulations. It expands on previous models by allowing for polydisperse micronized input drug, multiple suspended drugs, dissolved drug, and dissolved or suspended excipient to be included in the formulation. The model indicates that for most pMDI configurations, the majority of droplets contain no drug or a single drug particle and the residual particle size distribution delivered from the pMDI is essentially equivalent to the size distribution of the micronized drug used in the formulation. However, for pMDIs with a high drug concentration or that use small micronized drug particles, there can be a substantial fraction of the droplets that contain multiple drug particles. The residual particle size distribution obtained from these pMDIs can be substantially larger than the size distribution of the micronized drug. Excellent agreement was observed between size distributions predicted using this model and those obtained from experimental cascade impactor measurements (r 2 = 0.97), thus demonstrating the ability of the model to accurately predict the size distributions obtained from suspension pMDIs.
KW - Aerodynamic particle size
KW - Pressurized metered dose inhaler (pMDI)
KW - Simulation model
KW - Suspension formulation
UR - http://www.scopus.com/inward/record.url?scp=84655176372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84655176372&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2011.10.035
DO - 10.1016/j.ijpharm.2011.10.035
M3 - Article
C2 - 22044537
AN - SCOPUS:84655176372
SN - 0378-5173
VL - 422
SP - 101
EP - 115
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 1-2
ER -